

COVID-19 Ag+FLU A&B

Microfluidic Qualitative Immunoassay

The **FREND™ COVID-19 Ag+FLU A&B** is an easy-to-use fluorescence immunoassay (FIA) using the FREND™ System designed for the qualitative detection of the **nucleocapsid protein of SARS-CoV-2 and nucleoprotein of Influenza A and B strains** directly from individuals suspected with COVID-19 and/or flu. The FREND™ COVID-19 Ag+FLU A&B demonstrates reliable results in 3~4 minutes with **35 µL** of sample. No complicated process or training is required, thereby improving workflow efficiency.

Fast

3

mins

Easy


3

steps

Monitoring


LIS

Steps




STEP 01.

Rotate a swab in a lysis tube, attach a filter dropper and squeeze the sample into a specimen cup.



STEP 02.


Add **35 µL** of the sample.



STEP 03.

Insert the cartridge and get results.

Laboratory Information System Connectivity



In the event of a pandemic, the management of a vast amount of clinical results is important. As many laboratories face challenges in effective arrangement of the essential information⁽¹⁾, the **FREND™ System** provides the following advantages:

- Paperless
- Time-saving
- Automatic Data Transfer & Collection
- Convenient Data Management
- Can help monitoring (serosurveillance)

Clinical Performance Evaluation

A total of 338 samples (45 COVID-19 Ag positive, 293 negative; 38 Influenza A positive, 300 negative; 40 Influenza B positive, 298 negative) were tested with the FREND™ COVID-19 Ag+FLU A&B of which 95.56% PPA and 99.66% NPA were demonstrated for COVID-19 Ag. For Influenza A and Influenza B, PPA of 100% and 97.50% and NPA of 99.67% and 98.66% were demonstrated, respectively.

Reference Method: RT-PCR		
		COVID-19 Ag
FREND™ COVID-19 Ag+FLU A&B	PPA*	95.56% (43/45)
	NPA*	99.66% (292/293)

PPA

COVID-19 Ag
95.56%

Reference Method: RT-PCR			
		Influenza A	Influenza B
FREND™ COVID-19 Ag+FLU A&B	PPA	100.00% (38/38)	97.50% (39/40)
	NPA	99.67% (299/300)	98.66% (294/298)

FLU A
100.00%

FLU B
97.50%

* Positive Percent Agreement (PPA), Negative Percent Agreement (NPA)

Specification

Item	Specification
Assay principle	Fluorescence immunoassay
Specimen	Nasopharyngeal swab
Sample volume	35 µL
Reaction time	< 3 mins
Quantity	20 tests/kit
Storage condition	2~8 °C (35~46 °F)



Ordering Information

Product	Cat. No.
FREND™ System	F10
FREND™ COVID-19 Ag+FLU A&B	FRCGFL 020

Related Products

Cat. No.	Product	Quantity (tests/kit)
EPCO19 100	COVID-19 RT-PCR Kit	100
FRCOA 020	COVID-19 total Ab**	20
FRCOD 020	COVID-19 IgG/IgM Duo	20
FRCOG 020P	COVID-19 Ag	20
FRCOS 020	COVID-19 SP	20

** FDA EUA Approved



NESCT-FRCGFL-001E (V0.0)



Scan for more information.

NanoEntek, Inc.

Head Office

12F, 5, Digital-ro 26-gil, Guro-gu, Seoul, 08389, Korea
Tel:+82-2-6220-7940/Fax:+82-2-6220-7999

NanoEntek America, Inc.

Waltham, MA, USA Tel: +1-781-472-2558

NanoEntek Bio-Technology(Beijing) Ltd.

Fengtai District, Beijing Tel: +86-10-5920-7980

website

www.nanoentek.com

e-mail

ivdst@nanoentek.com